A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Strati P, Nastoupil LJ, Davis RE, Fayad LE, et al. Haematologica 2020;105:e26-e28.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Strati P, Nastoupil LJ, Davis RE, Fayad LE, et al. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 2020;105:e26-e28.
PMID: 31073068